Overview

Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder

Status:
RECRUITING

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Summary

This study is examining the use of Tezampanel (TZP) for treatment of Opioid Withdrawal Syndrome (OWS) in participants with Opioid Use Disorder (OUD). Participants will receive TZP or placebo (PBO) daily on Days 2 - 7 during a 7-day inpatient stay at the research center to determine safety, pharmacokinetic (PK) assessment, and efficacy of TZP for OWS.

Phase:

PHASE1

Details

Lead Sponsor:

Proniras Corporation

Collaborator:

Indiana University School of Medicine

Treatments:

tezampanel